---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-108762"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2023-10-12T23:59:59+00:00"
generated_at: "2026-06-10T00:40:37.810154+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech secures C$23M Canadian govt funding for EB05 Phase 3 ARDS study; CEO provides $10M credit facility

## Summary
- Government of Canada commits up to C$23M (US$17M) for Phase 3 study of EB05 (paridiprubart) in ARDS; C$5.75M non-repayable.
- Remaining C$17.25M conditionally repayable starting 2029 based on revenue growth; max repayment 1.4x principal.
- CEO Dr. Par Nijhawan provides $10M revolving credit facility, $3.5M immediate availability, at CIBC US Base Rate + 300bps, due March 31, 2026.
- Project must be completed by Dec 31, 2025, exclusively in Canada; includes regulatory submissions and manufacturing scale-up.
- Credit facility is a related-party transaction; borrowing base includes grant reimbursement and license fee receivables.

## SEC filing metadata
- accession: 0001104659-23-108762
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2023-10-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000110465923108762/0001104659-23-108762-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000110465923108762/tm2328265d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-108762
- JSON: https://secwatch.observer/filing/0001104659-23-108762.json
- Plain text: https://secwatch.observer/filing/0001104659-23-108762.txt

## Key facts
- Material Agreements
  Edesa Biotech, Inc. entered into Multi-Year Contribution Agreement with Government of Canada valued at up to CAD $23 million ($17 million USD) (effective 2023-10-12).
  - Action: entry
  - Counterparty: Government of Canada
  - Value: up to CAD $23 million ($17 million USD)
  - Effective: 2023-10-12
  source text: On October 12, 2023, Edesa Biotech Research, Inc. (“Edesa Biotech Research”), a wholly owned subsidiary of Edesa Biotech, Inc. (the “Company”) and the Company, as guarantor, entered into a multi-year contribution agreement (the “Agreement”) with the Government of Canada.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000110465923108762/0001104659-23-108762-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.